he purpose of this report was to update the 2006 International League Against Epilepsy (ILAE) report and identify the level of evidence for long-term efficacy or effectiveness for antiepileptic drugs (AEDs) as initial monotherapy for patients with newly diagnosed or untreated epilepsy. All applicable articles from July 2005 until March 2012 were identified, evaluated, and combined with the previous ysis (Glauser et al., 2006) to provide a comprehensive update.
The prior ysis methodology was utilized with three modifications: (1) the detectable noninferiority boundary approach was dropped and both failed superiority studies and prespecified noninferiority studies were yzed using a noninferiority approach, (2) the definition of an adequate comparator was clarified and now includes an absolute minimum point estimate for efficacy/effectiveness, and (3) the relationship table between clinical trial ratings, level of evidence, and conclusions no longer includes a recommendation column to reinforce that this review of efficacy/evidence for specific seizure types does not imply treatment recommendations.
This evidence review contains one clarification: The commission has determined that class I superiority studies can be designed to detect up to a 20% absolute (rather than relative) difference in the point estimate of efficacy/effectiveness between study treatment and comparator using an intent-to-treat ysis. Since July, 2005, three class I randomized controlled trials (RCT) and 11 class III RCTs he been published. The combined ysis (1940-2012) now includes a total of 64 RCTs (7 with class I evidence, 2 with class II evidence) and 11 meta-yses.
New efficacy/effectiveness findings include the following: levetiracetam and zonisamide he level A evidence in s with partial onset seizures and both ethosuximide and valproic acid he level A evidence in children with childhood absence epilepsy.
There are no major changes in the level of evidence for any other subgroup. Levetiracetam and zonisamide join carbamazepine and phenytoin with level A efficacy/effectiveness evidence as initial monotherapy for s with partial onset seizures. Although ethosuximide and valproic acid now he level A efficacy/effectiveness evidence as initial monotherapy for children with absence seizures, there continues to be an alarming lack of well designed, properly conducted epilepsy RCTs for patients with generalized seizures/epilepsies and in children in general.
These findings reinforce the need for multicenter, multinational efforts to design, conduct, and yze future clinically relevant adequately designed RCTs. When selecting a patient's AED, all relevant variables and not just efficacy and effectiveness should be considered.
核对信源地址
编辑: jiang上一页:癫痫病的常见病因有哪些
下一页:癫痫病确诊的主要依据
- 2022-05-04ESC 2020访谈:马长生:ABC途径让房颤管理更简洁,NOAC广泛应用将推动抗凝治疗率强化
- 2022-05-02关于妊娠期TORCH前列腺癌的53个问答
- 2022-04-21癫痫病发作的状况都有哪些
- 2022-04-12控制癫痫患者再次抽搐,不包括可选药物?
- 2022-04-11预测癫痫患者再入院风险
- 2022-04-06美国神经病学协会的新指南帮助医生HIV癫痫药物更适合患者
- FDA批准Aptiom用于治疗患者癫痫发作
- 控制癫痫患者再次抽搐,不包括可选药物?
- 预测癫痫患者再入院风险
- 病例报告:水浴 PUVA 治疗皮下环状肉芽肿
- 治疗白癜风的阿普斯特临床数据
- 美国神经病学协会的新指南帮助医生HIV癫痫药物更适合患者
- 抗癫痫药物预防新发癫痫:任重而道远
- FDA批准开浦兰治疗1个月至4岁癫痫儿童
- 白癜风光疗有很多方法 因地制宜教你选择
- 白癜风的病因是什么?
- 晚餐吃什么减肥?这样吃饭很容易减肥
- FDA警告怀孕期间使用丙戊酸钠药物
- Pharmaceutics:局部治疗念珠菌感染的脂质体槲皮素和无食子酸
- 脑梗死的症状是什么有这些前兆要谨慎
- 黑头怎么去?
- 元宵节吃汤圆送灯
- 2015 神经系统疾病诊疗进展
- 癫痫会遗传吗 癫痫的治疗方法
- UCB的Vimpat癫痫新适应症在美国获批
- 癫痫患者手术评估新型工具
- 月经性癫痫患者妊娠期癫痫控制更好
- 夏季生活常识 酷夏保健秘籍你知道多少(2)
- 染发有什么危害 喜欢掉头发的原因
- 罕见病例:自发性颞极性扩张伴癫痫发作
- 2015第31届国际癫痫大会(IEC)
- 私密┃月经结束了。内衣上这些棕色的东西是什么?
- 白癜风患者吃生葵花子有助于治疗吗?
- 泡温泉时不能忽视的事情
- 癫痫病的治疗方法有哪些常用方式将
- 专家知道你癫痫病的治疗好方法
- 成年人癫痫病怎么治疗才能有效
- Radiology:利用MR识别评价内侧颞叶癫痫病灶的价值
- 癫痫病人的发作因素是什么
- 前瞻性研究表明癫痫与卒中所之间存在联系
- 癫痫病只能怎样来进行诊断
- 治疗癫痫病方法有哪种最有效
- 脑部疾病是癫痫病的首要致病
- 第五届 CAAE 国际癫痫研讨会
- 痫病症的治疗方法是什么 痫病症有这些偏方
- 癫痫病治疗后只能多久能康复